Chronic lymphocytic leukemia: New concepts and emerging therapies

  • Ahmadi T
  • Maniar T
  • Schuster S
 et al. 
  • 3

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Remarkable progress in elucidating the biology of chronic lymphocytic leukemia (CLL) has been made over the last two decades. Improved understanding of CLL has lead to new prognostic tools and therapeutic options, and holds promise for eventually finding a cure for this disease. Challenges lie in incorporating the various treatment modalities, including chemotherapy, monoclonal antibodies, immunotherapeutic strategies and novel small molecules, into a comprehensive treatment strategy guided by the biological complexity of CLL. © Current Medicine Group LLC 2009.

Author-supplied keywords

  • Antibodies, Monoclonal
  • Antigens, CD5
  • Antineoplastic Combined Chemotherapy Protocols
  • B-Lymphocyte Subsets
  • CD23 antigen
  • CD38 antigen
  • Disease Progression
  • Drugs, Investigational
  • Humans
  • Immunologic Factors
  • Immunotherapy
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Multicenter Studies as Topic
  • Neoplasm, Residual
  • Nitrogen Mustard Compounds
  • Randomized Controlled Trials as Topic
  • abt 263
  • alemtuzumab
  • alkylating agent
  • allogeneic stem cell transplantation
  • allopurinol
  • anemia
  • antineoplastic activity
  • antineoplastic agent
  • bendamustine
  • beta 2 microglobulin
  • bone marrow suppression
  • cancer combination chemotherapy
  • cancer growth
  • cancer immunotherapy
  • cancer radiotherapy
  • cancer recurrence
  • cancer relapse
  • cancer staging
  • cancer survival
  • chlorambucil
  • chronic lymphatic leukemia
  • cisplatin
  • clinical trial
  • cyclophosphamide
  • disease marker
  • dosage schedule comparison
  • dose response
  • doxorubicin
  • drug clearance
  • drug dose escalation
  • drug dose reduction
  • drug dose sequence
  • drug efficacy
  • drug fatality
  • drug protein binding
  • drug safety
  • drug substitution
  • drug tolerability
  • drug withdrawal
  • dyspnea
  • fatigue
  • flavopiridol
  • fludarabine
  • human
  • hydration
  • infection
  • lenalidomide
  • leukopenia
  • low drug dose
  • lumiliximab
  • lymphocytoma
  • mantle cell lymphoma
  • minimal residual disease
  • mitoxantrone
  • multiple cycle treatment
  • nausea
  • neutropenia
  • nonhodgkin lymphoma
  • oblimersen
  • ofatumumab
  • optimal drug dose
  • pentostatin
  • prednisolone
  • prognosis
  • protein expression
  • protein kinase ZAP 70
  • recommended drug dose
  • reduced intensity conditioning
  • review
  • rituximab
  • salvage therapy
  • thrombocytopenia
  • thymidine kinase
  • treatment indication
  • treatment planning
  • treatment response
  • tumor flare
  • tumor lysis syndrome
  • unclassified drug
  • unspecified side effect
  • vincristine
  • vomiting

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Authors

  • T Ahmadi

  • T Maniar

  • S Schuster

  • E Stadtmauer

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free